机构:[1]Department of Urology/Institute of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan, China四川大学华西医院[2]Department of Urology, Peking University Shenzhen Hospital, Shenzhen, Guangdong, China北京大学深圳医院深圳市康宁医院深圳医学信息中心[3]Department of Urology, West China Xiamen Hospital of Sichuan University, Xiamen, Fujian, China
The study was supported by the National Natural Science Foundation
of China (No. 82203298).
语种:
外文
PubmedID:
中科院(CAS)分区:
出版当年[2023]版:
大类|2 区医学
小类|2 区医学:研究与实验2 区药学
最新[2023]版:
大类|2 区医学
小类|2 区医学:研究与实验2 区药学
第一作者:
第一作者机构:[1]Department of Urology/Institute of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan, China
共同第一作者:
通讯作者:
通讯机构:[*1]Department of Urology, Institute of Urology, West China Hospital, Sichuan University, 37 Guoxue.Alley, Chengdu 610041, China
推荐引用方式(GB/T 7714):
Wang Jiahao,Ren Junwei,Tu Xiang,et al.ARNTL2 facilitates bladder cancer progression through potentiating ENO1-mediated glycolysis in a SLC31A1-independent and -dependent manner[J].Life Sciences.2024,355:122974.doi:10.1016/j.lfs.2024.122974.
APA:
Wang Jiahao,Ren Junwei,Tu Xiang,Yuan Haichao,Ye Zhenyang...&Bai Yunjin.(2024).ARNTL2 facilitates bladder cancer progression through potentiating ENO1-mediated glycolysis in a SLC31A1-independent and -dependent manner.Life Sciences,355,
MLA:
Wang Jiahao,et al."ARNTL2 facilitates bladder cancer progression through potentiating ENO1-mediated glycolysis in a SLC31A1-independent and -dependent manner".Life Sciences 355.(2024):122974